Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BMXMF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BMXMF and 80,000+ other tickers.
See exactly how BMXMF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BMXMF and 80,000+ other tickers.
Operating on a global scale, bioMérieux S.A. designs and produces in vitro diagnostic solutions specifically for detecting infectious diseases across the Americas, Europe, the Middle East, Africa, and Asia Pacific. The firm's offerings encompass diagnostic systems that analyze biological samples to identify infectious diseases, cardiovascular conditions, and various types of cancer. Furthermore, it provides essential microbiological testing for quality assurance within the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele includes clinical and hospital…
bioMérieux S.A. (BMXXY) Q1 2026 Sales/Trading Call Transcript
HealthEquity (NASDAQ: HQY - Get Free Report) and bioMerieux (OTCMKTS:BMXMF - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Institutional and Insider Ownership 99.6% of HealthEquity shares are held
Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) gapped up prior to trading on Friday. The stock had previously closed at $109.61, but opened at $115.00. bioMerieux shares last traded at $115.00, with a volume of 1,012 shares trading hands. Analysts Set New Price Targets Separately, BNP Paribas Exane cut shares of bioMerieux to
bioMérieux S.A. (BMXXY) Q4 2025 Earnings Call Transcript
bioMérieux S.A. (OTCPK:BMXXY) Analyst/Investor Day November 4, 2025 8:30 AM EST Company Participants Aymeric Fichet Pierre Boulud - Chief Executive Officer Guillaume Bouhours - Executive VP of Purchasing and Information Systems & CFO Conference Call Participants Odysseas Manesiotis - BNP Paribas, Research Division Anchal Verma - JPMorgan Chase & Co, Research Division Aisyah Noor - Morgan Stanley, Research Division Dylan van Haaften - Stifel, Nicolaus & Company, Incorporated, Research Division Jan Koch - Deutsche Bank AG, Research Division Natalia Webster - RBC Capital Markets, Research Division Kavya Deshpande - UBS Investment Bank, Research Division Presentation Operator Welcome to the bioMérieux 2025 Third Quarter Sales Conference Call.